Overview
Real-World Perspectives on the Role of TYK2 Inhibitors in the Treatment of Psoriasis
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
How are TYK2 inhibitors different from conventional JAK inhibitors? In what patient population would they be best suited? Find out in this expert-led clinical review and panel discussion that provides the knowledge you need on the investigational TYK2 inhibitors and their potential roles in personalized psoriasis treatment plans. This content is available across two modules, allowing you to choose where to focus your time.
Discussion topics include:
• TYK2 role in psoriasis pathogenesis
• Latest TYK2 inhibitor clinical evidence
• How to differentiate TYK2 inhibitors from conventional JAK inhibitors
• Current psoriasis treatment paradigms
• TYK2 inhibitor potential place in therapy
• Shared decision-making in psoriasis care
This activity is intended for medical dermatologists, dermatology NPs & PAs, primary care providers, and other healthcare providers who treat patients with psoriasis.
It has been well documented that psoriasis is undertreated, and patients are often unsatisfied with their psoriasis treatments. Fortunately, exploration into new pathways has given hope to clinicians, as the emergence of JAK inhibitors are creating new treatment options for patients are unsatisfied with their psoriasis treatment. As new science, particularly with TYK2 inhibition, continues to unfold and implications for practice are better understood, clinicians across the country need to be made aware. Following this activity, learners will become more familiar with the emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy, and routes and administration. Learners will also be better able to see how these TYK2 inhibitors can help overcome present barriers in psoriasis care and identify the roles these agents can play in treatment plans.
Upon completion of this activity, participants will be able to:
• Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes of administration
• Assess clinical implications of emerging evidence for in meeting unmet clinical needs for refractory psoriasis patients
• Model current and future treatment strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors
• Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes of administration
• Assess clinical implications of emerging evidence for in meeting unmet clinical needs for refractory psoriasis patients
• Model current and future treatment strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors
This activity is sponsored by the Academy for Continued Healthcare Learning.
This activity is supported by an educational grant from Bristol-Myers Squibb.
April Armstrong, MD, MPH
Professor of Dermatology
Associate Dean for Clinical Research
Director of Clinical Research Support, Southern California Clinical and Translational Science Institute
Vice Chair | Director, Clinical Trials and Outcomes Research | Director, Psoriasis Program
Department of Dermatology
Keck School of Medicine at USC
University of Southern California
Los Angeles, CA
Professor of Dermatology
Associate Dean for Clinical Research
Director of Clinical Research Support, Southern California Clinical and Translational Science Institute
Vice Chair | Director, Clinical Trials and Outcomes Research | Director, Psoriasis Program
Department of Dermatology
Keck School of Medicine at USC
University of Southern California
Los Angeles, CA
Neal Bhatia, MD
Director of Clinical Dermatology
Therapeutics Clinical Research
San Diego, CA
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
April Armstrong, MD, MPH
Consultant (Occasional): AbbVie, ASLAN Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Sun Dermatology, UCB
Grant/Research Support recipient: Bristol-Myers Squibb, Dermavant, Dermira, Leo, Lilly, Pfizer, UCB
Neal Bhatia, MD
Consultant (Occasional): Almirall, Biofrontera AG, Castle Biosciences, Dermavant Sciences, DermTech Inc., EPI Health, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., ISDIN, La Roche-Posay Laboratorie Pharmaceutique, Mayne Pharma Group, Ortho Dermatologics, Sanofi/Regeneron, Sonoma Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Vyome Therapeutics Limited
Grant/Research Support recipient (Investigator): AbbVie, Amgen, Arcutis, Inc., Atacama Therapeutics, Brickell Biotech, Inc., Bristol-Myers Squibb, Dermira, Dr. Reddy's Laboratories Ltd., DUSA Pharmaceuticals, Inc., Foamix, LEO Pharma, US, MC2 Therapeutics, Menlo Therapeutics, Pfizer Inc., Sanofi/Regeneron, Sol-Gel Technologies, Soligenix, Inc, Sun Pharmaceutical Industries Ltd., UCB, Vyome Therapeutics Limited
Other Support (Honorarium): Johnson and Johnson Consumer Products Company, Practical Dermatology
The following financial relationships have been provided:
April Armstrong, MD, MPH
Consultant (Occasional): AbbVie, ASLAN Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Sun Dermatology, UCB
Grant/Research Support recipient: Bristol-Myers Squibb, Dermavant, Dermira, Leo, Lilly, Pfizer, UCB
Neal Bhatia, MD
Consultant (Occasional): Almirall, Biofrontera AG, Castle Biosciences, Dermavant Sciences, DermTech Inc., EPI Health, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., ISDIN, La Roche-Posay Laboratorie Pharmaceutique, Mayne Pharma Group, Ortho Dermatologics, Sanofi/Regeneron, Sonoma Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Vyome Therapeutics Limited
Grant/Research Support recipient (Investigator): AbbVie, Amgen, Arcutis, Inc., Atacama Therapeutics, Brickell Biotech, Inc., Bristol-Myers Squibb, Dermira, Dr. Reddy's Laboratories Ltd., DUSA Pharmaceuticals, Inc., Foamix, LEO Pharma, US, MC2 Therapeutics, Menlo Therapeutics, Pfizer Inc., Sanofi/Regeneron, Sol-Gel Technologies, Soligenix, Inc, Sun Pharmaceutical Industries Ltd., UCB, Vyome Therapeutics Limited
Other Support (Honorarium): Johnson and Johnson Consumer Products Company, Practical Dermatology
Mark Lebwohl, MD
Consultant: Aditum Bio, Almirall, AnaptysBio, Arcutis Biotherapeutics, Aristea Therapeutics, Arrive Technologies, Inc., Avotres Therapeutics LLC, BiomX Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, LLC, Dermavant Sciences, Dr. Reddy's Laboratories Ltd., Evelo Biosciences, Evommune, Inc., Forte Biosciences Inc., Helsinn Therapeutics, LEO Pharma Inc., Meiji Seika Pharma Co., Ltd., Pfizer Inc., Verrica Pharmaceuticals
Research Funds: Abbvie, Amgen, Arcutis Biotherapeutics, Avotres Inc., Boehringer Ingelheim, Dermavant Sciences, Eli Lilly and Company, Incyte, Janssen, Ortho Dermatologics, Inc., Regeneron Pharmaceuticals, UCB
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: investigational deucravacitinib and off-label cyclosporine
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
